Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

You can call today's PR whatever you like, but it won't change the FACT that a stage 4 thymoma patient has stable disease and a ~6% tumor reduction in a Phase 1 safety trial.

Today's PR was a disgrace whether you look at from a GCP or a CSR perspective.